Biograph tp16

Manufactured by Siemens

The Biograph TP16 is a positron emission tomography (PET) scanner designed for research applications. It features a 16-ring detector system and can perform whole-body imaging. The device is capable of high-resolution PET imaging but further details on its technical specifications or intended use are not available.

Automatically generated - may contain errors

Lab products found in correlation

Gemini tf 16, by Philips (5 mentions) Gemini tf64, by Philips (5 mentions) Gemini gxl, by Philips (5 mentions) Discovery ls, by GE Healthcare (4 mentions) Biograph mct 20 flow, by Siemens (2 mentions) Biograph 6, by Siemens (2 mentions) Discovery ste, by GE Healthcare (1 mentions) Discovery iq, by GE Healthcare (1 mentions) Discovery st, by GE Healthcare (1 mentions)

5 protocols using biograph tp16

Standardized Whole-Body PET/CT Imaging

Check if the same lab product or an alternative is used in the 5 most similar protocols

PET/CT studies were obtained on the following PET/CT devices: Gemini TF64 (Philips), Gemini GXL (Philips), Gemini TF16 (Philips), Discovery LS (GE Healthcare), and Biograph TP16 (Siemens). Subjects with fasting serum glucose <7.0 mmol/L >6 h received IV ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG) 3.70−5.55 MBq/Kg. After 60 min whole-body PET/CT imaging was performed with a whole-body CT scan (120 KV and 140 mA) and a whole-body PET (in 3-dimensional mode, 120s/bed position). Acquisition of CT, PET and PET/CT fusion images including cross-section, sagittal-section and coronal-section used CT-based attenuation correction in reconstruction image by an iterative method.

Liang J.H., Ding C.Y., Gale R.P., Wang L., Xu J., Qu X.Y., Fan L., Li T.L., Li J.Y, & Xu W. (2016). Prognostic value of whole-body SUVmax of nodal and extra-nodal lesions detected by 18F-FDG PET/CT in extra-nodal NK/T-cell lymphoma. Oncotarget, 8(1), 1737-1743.

+ Open protocol

+ Expand

PET/CT Imaging Protocol for Bone Marrow Evaluation

Check if the same lab product or an alternative is used in the 5 most similar protocols

PET/CT studies were carried out using the following PET/CT devices: Gemini TF64, Gemini GXL, and Gemini TF16 (all three Gemini devices from Philips), Discovery LS (GE Healthcare), and either Biograph mCT 20 Flow, Biograph TP16 and Biograph 6 (the last three from Siemens). Procedure, quality control, and interpretation guidelines are commented in detail in our previous work 10. Briefly, the low‐dose CT components of the PET/CT were used for both co‐localization and attenuation correction of the PET emission data.
Coronal, sagittal, and transversal PET/CT projections were reconstructed by iterative methods and analyzed using the manufacturers′ software. Image interpretation was performed by qualitative (visual) analysis, considering the presence or absence of BMI using glucose activity in the liver as a reference. If present, bone marrow lesions were characterized as focal lesions or diffuse uptake exceeding that of the liver. Semiquantitative analysis was performed by means of the maximum standardized uptake value (SUVmax), normalized to body weight, as the voxel with maximum uptake in a region or volume of interest.

Chen‐Liang T., Martín‐Santos T., Jerez A., Rodríguez‐García G., Senent L., Martínez‐Millán C., Muiña B., Orero M., Teruel A., Martín A., Gómez‐Espuch J., Kennedy K., Benet C., Raya J.M., Fernández‐González M., de la Cruz F., Guinot M., Villegas C., Ballester I., Baile M., Moya M., López‐Jiménez J., Frutos L., Navarro J.L., Uña J., Fernández‐López R., Igua C., Contreras J., Sánchez‐Vañó R., Cozar M.D., Tamayo P., Mucientes J., Sánchez‐Blanco J.J., Pérez‐Ceballos E, & Ortuño F.J. (2017). Bone marrow biopsy superiority over PET/CT in predicting progression‐free survival in a homogeneously‐treated cohort of diffuse large B‐cell lymphoma. Cancer Medicine, 6(11), 2507-2514.

+ Open protocol

+ Expand

PET-CT Imaging Protocol for Glucose Metabolism

Check if the same lab product or an alternative is used in the 5 most similar protocols

PET-CT studies were obtained on the following PET-CT devices: Gemini TF64 (Philips, Best, Netherlands), Gemini GXL (Philips, Eindhoven, Netherlands), Gemini TF16 (Philips, Eindhoven, Netherlands), Discovery LS (GE Healthcare, Milwaukee, WI), and Biograph TP16 (Siemens, Erlangen, Germany). Subjects with fasting serum glucose < 7.0 mmol/L received ¹⁸F-FDG 3.70-5.55 MBq/kg intrave-nously for > 6 hours. After 60-minute whole-body PET-CT imaging was performed with a whole-body CT scan (120 KV and 140 mA) and a whole-body PET (in 3-dimensional mode, 120 sec/bed position). Acquisition of CT, PET, and PET-CT fusion images including cross-section, sagittal-section and coronal-section used CT-based attenuation correction in reconstruction image by an iterative method.

Liang J.H., Zhang Y.P., Xia J., Ding C.Y., Wu W., Wang L., Cao L., Zhu H.Y., Fan L., Li T.N., Li J.Y, & Xu W. (2019). Prognostic Value of Baseline and Interim Total Metabolic Tumor Volume and Total Lesion Glycolysis Measured on 18F-FDG PET-CT in Patients with Follicular Lymphoma. Cancer Research and Treatment : Official Journal of Korean Cancer Association, 51(4), 1479-1487.

+ Open protocol

+ Expand

PET/CT Imaging of Brown Adipose Tissue

Check if the same lab product or an alternative is used in the 5 most similar protocols

PET/CT studies were obtained by the following PET/CT devices: Gemini TF64, Gemini GXL and Gemini TF16 (Gemini devices from Philips), Discovery LS, Discovery ST, Discovery STE and Discovery IQ (Discovery devices from GE Healthcare), and either Biograph mCT 20 Flow, Biograph TP16 and Biograph 6 (Biograph devices from Siemens). Procedure, quality control and interpretation guidelines are commented in detail in our previous works.¹³, ¹⁷ BMI by PET/CT was considered positive with the presence of unifocal (single lesion), bifocal, multifocal (≥3 lesions) or focal lesions with diffuse uptake. Purely diffuse FDG uptake was not considered BMI.

Ródenas‐Quiñonero I., Chen‐Liang T., Martín‐Santos T., Salar A., Fernández‐González M., Celades C., Navarro J., Martínez‐Garcia A.B., Andreu R., Balaguer A., Martin García‐Sancho A., Baile M., López‐Jiménez J., Marquet‐Palomanes J., Teruel A.I., Terol M.J., Benet C., Frutos L., Navarro J.L., Uña J., Suarez M., Cortes M., Contreras J., Ruiz C., Tamayo P., Mucientes J., Sopena‐Novales P., Reguilón‐Gallego L., Sánchez‐Blanco J.J., Pérez‐Ceballos E., Jerez A, & Ortuño F.J. (2022). Accuracy and prognostic impact of FDG PET/CT and biopsy in bone marrow assessment of follicular lymphoma at diagnosis: A Nation‐Wide cohort study. Cancer Medicine, 12(6), 6536-6546.

+ Open protocol

+ Expand

18F-FDG PET/CT Scanning Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

All 18F-FDG PET/CT baseline scans were performed as whole-body scans (from the base of the skull to midthigh) after a 6-hr fasting period. Patients underwent blood glucose tests prior to administering 18F-FDG to ensure suitably low levels, received adequate pre-hydration, remained recumbent and silent in warm room to ensure fewer artifacts and to minimize 18F-FDG uptake in muscles and brown fat activation.
PET/CT studies were obtained on the following PET/CT devices: Gemini TF64 (Philips), Gemini GXL (Philips), Gemini TF16 (Philips), Discovery LS (GE Healthcare), and Biograph TP16 (Siemens) according to the local
3 institutional scanning protocols. The emission data were acquired for 2-5 min per bed position (based on the available scan system) starting 60-90 min after intravenous injection of the body weight-adapted FDG dosage recommended according to the manufacturer guidelines for each scan model. Quality control procedures were carried out at regular intervals for all devices with strict adherence to local protocols, manufacturer guidelines, and EANM guidelines.
The low dose CT components of the PET/CT were used for both co-localization and attenuation correction of the PET emission data. Coronal, sagittal, and transversal PET/CT projections were reconstructed by iterative methods and analyzed using the manufacturers' software.

Cistaro A., Cassalia L., Ferrara C., Quartuccio N., Evangelista L., Bianchi M., Fagioli F., Bisi G., Baldari S., Zanella A., Pillon M., Zucchetta P., Burei M., Sala A., Guerra L., Guglielmo P., Burnelli R., Panareo S., Scalorbi F., Rambaldi I., Piccardo A., Garaventa A., Familiari D., Fornito M.C., Lopci E., Mascarin M., Altini C., Ferrari C., Perillo T., Santoro N., Borsatti E, & Rubini G. (2018). Italian Multicenter Study on Accuracy of ¹⁸F-FDG PET/CT in Assessing Bone Marrow Involvement in Pediatric Hodgkin Lymphoma. Clinical lymphoma, myeloma & leukemia, 18(6).

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!